Personalized mRNA Neoantigen Vaccines in Cancer: From Tumor Sequencing to Phase 3 Clinical Evidence
Year: 2026
Type: study-registration
Abstract: Personalized mRNA Neoantigen Vaccines in Cancer: From Tumor Sequencing to Phase 3 Clinical Evidence Research Project Description Background and Rationale Cancer immunotherapy has transformed the treatment of several advanced malignancies, particularly through immune checkpoint inhibitors that restore or enhance antitumor T-cell activity. However, many tumors remain resistant to immunotherapy, and responses can vary substantially between patients. One major reason is the biological heterogeneity of tumors and the differences in tumor-specific antigens that can be recognized by the immune system. Neoantigens are tumor-specific protein sequences generated by somatic mutations in cancer cells. Because they are absent, or largely absent, from normal tissues, neoantigens represent attractive targets for highly specific cancer immunotherapy. Advances in next-generation sequencing, computational biology, artificial intelligence, and messenger RNA (mRNA) vaccine technology have made it possible to develop individualized vaccines containing multiple neoantigens selected from a patient's own tumor. Personalized mRNA neoantigen vaccines aim to train the patient's immune system to recognize and eliminate cancer cells carrying these tumor-specific mutations. Unlike conventional vaccines, which are designed for pathogens or shared tumor antigens, personalized neoantigen vaccines are manufactured according to the molecular characteristics of an individual patient's tumor. This creates a highly individualized therapeutic approach in which tumor sequencing directly informs vaccine design. This research project will examine the development and clinical translation of personalized mRNA neoantigen vaccines, following the process from tumor sampling and genomic sequencing through neoantigen identification, computational vaccine design, mRNA manufacturing, immune activation, and clinical evaluation. Particular attention will be given to the clinical evidence emerging from randomized trials and Phase 3 development programs. Purpose of the Research The primary purpose of this project is to critically evaluate how personalized mRNA neoantigen vaccines are designed, developed, and translated into clinical cancer treatment, and to determine whether available evidence supports their potential to improve clinical outcomes when used alone or in combination with standard immunotherapies. The project will specifically investigate: 1. How tumor sequencing is used to identify patient-specific mutations and potential neoantigens. 2. How computational algorithms predict which mutations are most likely to generate immunogenic neoantigens. 3. How selected neoantigens are incorporated into individualized mRNA vaccine constructs. 4. How mRNA vaccines stimulate tumor-specific CD4+ and CD8+ T-cell responses. 5. How personalized vaccination interacts with immune checkpoint blockade and other cancer therapies. 6. Whether vaccine-induced immune responses translate into measurable clinical benefits, including reduced recurrence and improved progression-free and overall survival. 7. How evidence has progressed from early-phase clinical studies to randomized Phase 2 and Phase 3 trials. 8. What technical, biological, manufacturing, and clinical challenges must be addressed before personalized neoantigen vaccination can become broadly available. Research Approach The project will use a translational research framework that connects molecular tumor profiling with clinical outcomes. 1. Tumor Collection and Sequencing The process begins with obtaining tumor tissue and, where appropriate, matched normal tissue or blood. Tumor DNA and RNA can be analyzed using next-generation sequencing approaches such as whole-exome sequencing, whole-genome sequencing, and transcriptomic profiling. Sequencing identifies somatic alterations, including single-nucleotide variants, insertions and deletions, and other genomic changes that may produce abnormal peptides. The project will examine how the quality and depth of tumor sequencing influence the number and reliability of candidate neoantigens identified. 2. Neoantigen Identification and Prediction Not every tumor mutation produces an effective immune target. Candidate mutations therefore undergo computational analysis to determine whether they are expressed and whether the resulting peptides are likely to be presented by the patient's human leukocyte antigen (HLA) molecules. Bioinformatic pipelines can integrate mutation calls, gene-expression data, HLA typing, peptide-HLA binding predictions, and other features to rank candidate neoantigens. The project will evaluate the strengths and limitations of these prediction approaches, including the possibility of false-positive predictions and the difficulty of accurately predicting which neoantigens will generate functional T-cell responses. 3. Personalized Vaccine Design After candidate neoantigens are prioritized, a set of targets can be incorporated into an individualized mRNA vaccine. The mRNA provides cells with temporary instructions to produce the selected antigenic sequences, allowing antigen-presenting cells to process and present them to the immune system. A major advantage of the mRNA platform is its flexibility: multiple neoantigens can be encoded within a single vaccine, potentially allowing the immune system to target several independent tumor mutations simultaneously. This multi-target approach may reduce the likelihood that cancer cells can escape immune recognition through the loss or alteration of a single antigen. 4. Immune Activation Following vaccination, the mRNA is taken up by cells and translated into the encoded antigenic proteins or peptides. These antigens can subsequently be presented through major histocompatibility complex pathways, activating tumor-specific T cells. The project will assess evidence for both CD8+ cytotoxic T-cell responses, which can directly kill tumor cells, and CD4+ helper T-cell responses, which can support and sustain antitumor immunity. Immune monitoring may include assays measuring neoantigen-specific T-cell expansion, cytokine production, T-cell receptor responses, and recognition of tumor cells. 5. Combination With Immune Checkpoint Inhibitors An important component of current neoantigen vaccine development is combination therapy with immune checkpoint inhibitors. Although vaccination can generate or expand tumor-specific T cells, tumors may suppress these T cells through inhibitory pathways such as PD-1/PD-L1. Checkpoint blockade can therefore complement vaccination by reducing immune suppression and allowing vaccine-induced T cells to function more effectively. The project will examine clinical evidence for combinations of personalized mRNA vaccines with checkpoint inhibitors, particularly anti-PD-1 therapies. Clinical Evidence and Phase 3 Translation A central component of this research will be a critical assessment of clinical evidence across the development pathway. Early clinical studies have demonstrated that personalized neoantigen vaccination is technically feasible and can generate measurable immune responses against multiple tumor-specific targets. Subsequent randomized studies have provided evidence that vaccination combined with immune checkpoint blockade may improve clinical outcomes in selected cancers. One of the most important clinical developments has been the evaluation of the personalized mRNA-4157/V940 vaccine in combination with pembrolizumab in melanoma. Earlier randomized evidence reported improved recurrence-related outcomes compared with pembrolizumab alone, supporting progression toward late-stage clinical development. The field has subsequently moved into Phase 3 evaluation, including large randomized trials designed to determine whether the addition of a personalized neoantigen vaccine produces a clinically meaningful improvement in recurrence-free and other cancer outcomes. A key objective of this project will therefore be to distinguish promising Phase 2 evidence from definitive Phase 3 evidence. Where Phase 3 trials remain ongoing or results are not yet mature, the project will explicitly identify this limitation rather than treating investigational findings as established clinical benefit. The analysis will compare endpoints such as recurrence-free survival, distant metastasis-free survival, event-free survival, progression-free survival, overall survival where available, objective response rates in advanced disease, and the durability of vaccine-induced immune responses. Safety and Feasibility The research will also evaluate the safety profile and practical feasibility of individualized mRNA vaccination. Particular attention will be paid to treatment-related adverse events, immune-related adverse events associated with checkpoint inhibition, vaccine-associated systemic reactions, and serious adverse events. A major translational challenge is manufacturing speed. Because each vaccine is designed according to an individual patient's tumor mutations, treatment requires a coordinated workflow involving tumor sampling, sequencing, computational analysis, antigen selection, vaccine design, manufacturing, quality control, and administration. The project will investigate how improvements in sequencing and manufacturing technologies could shorten this process and make personalized vaccination more scalable. Expected Outcomes The project is expected to produce a comprehensive assessment of the scientific and clinical development of personalized mRNA neoantigen vaccines. The anticipated outcomes include: A detailed description of the molecular pipeline used to move from tumor sequencing to personalized vaccine production. Identification of the principal computational and biological factors determining successful neoantigen selection. An evaluation of the ability of personalized mRNA vaccines to generate tumor-specific T-cell responses. A critical synthesis of clinic
Source: Open Science Framework
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7206166182